| Nov 11 |
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
|
| Nov 11 |
Spravato is just the beginning in a new wave of depression meds
|
| Nov 8 |
Why Johnson & Johnson (JNJ)’s Legal Issues Could Wrap Up Quickly
|
| Nov 8 |
J&J seeks approval of Darzalex for early-stage multiple myeloma
|
| Nov 8 |
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
|
| Nov 8 |
Johnson & Johnson MedTech’s VARIPULSE Platform receives FDA approval for AFib
|
| Nov 7 |
FDA Greenlights J&J's Varipulse Device for Safer Atrial Fibrillation Treatment
|
| Nov 7 |
J&J wins approval of Varipulse atrial fibrillation device
|
| Nov 7 |
Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
|
| Nov 7 |
J&J wins FDA approval for Varipulse PFA system
|
